CFRX: Four Abstracts Published in 30th ECCMID Abstract Book; Financing Overhang Removed as Pfizer Makes Second Investment...
ContraFect is a clinical-stage biotechnology company focused on discovering, differentiated biologic therapeutics and developing them for the treatment of life-threatening infectious diseases, including those caused by drug-resistant pathogens. The company's program, CF-301 (exebacase), is an investigational lysin targeting Staph aureus, including methicillin-resistant strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis. Exebacase is being studied in a Phase 2 superiority study to evaluate its safety and pharmacokinetics when used in addition to standard of care antibiotics for the treatment of Staph aureus bacteremia, including endocarditis in adult patients.
Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.